OakChart

Intelligent Bio Solutions Inc

INBSHealthcare·Medical Devices·USA·Nano·NASD·Nov 11 • 3:59 PM ET

2.10-0.15 (-6.67%)
2026-11-11 22:36 CET
Market cap
7.46 USD m
Revenue, TTM
4.50 USD m
Net income, TTM
-12.11 USD m
Free cash flow, TTM
-12.22 USD m
EPS diluted, TTM
-6.82
P/E
-
Compare

Price

INBS against its 20, 50 and 200-day averages
2050200earnings
2.004.006.008.002.5M5.0MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26INBSclose 2.1020-day 1.7750-day 1.81200-day 2.802.1052w low

91.6% under the 52-week high of 24.90 on 12 Jan 2026. 52-week low 1.35 on 14 Oct 2026. Last 15 sessions, 48.7% high to low

Volume 0.62× normal · the line is the 50-bar volume average

Profile

INBS
52-week range, 3% of the way up
1.3524.90

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Employees58
IPODec 23, 2020
Beta4.44
ATR, 14d0.17
Rel volume0.62
Short float1.97%
Insider own2.99%
Inst own5.71%

Snapshot

6 groups

Valuation

Index-
Market Cap6.96M
Enterprise Value2.59M
Income-12.11M
Sales4.50M
Book/sh2.29
Cash/sh1.79
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees58
IPODec 23, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S1.55
P/B0.92
P/C1.17
P/FCF-
EV/EBITDA-
EV/Sales0.58
Quick Ratio1.87
Current Ratio1.98
Debt/Eq0.24
LT Debt/Eq0.22
Option/ShortNo / Yes

Earnings

EPS (ttm)-6.82
EPS next Y-4.06
EPS next Q-1.36
EPS this Y38.63%
EPS next Y21.62%
EPS next 5Y-
EPS past 3/5Y81.20% 65.06%
Sales past 3/5Y49.68% -
EPS Y/Y TTM60.09%
Sales Y/Y TTM36.55%
EPS Q/Q75.39%
Sales Q/Q25.19%
EarningsNov 10 BMO
EPS/Sales Surpr.34.35% -0.59%

Ownership

Insider Own2.99%
Insider Trans0.00%
Inst Own5.71%
Inst Trans-0.58%
ROA-102.34%
ROE-216.11%
ROIC-131.33%
Gross Margin26.52%
Oper. Margin-286.70%
Profit Margin-269.31%
SMA2018.93%
SMA5016.02%
SMA200-25.07%
Trades-

Technical

Shs Outstand3.32M
Shs Float3.22M
Short Float1.97%
Short Ratio0.44
Short Interest0.06M
52W High24.90 -91.57%
52W Low1.35 55.56%
Volatility10.01% 8.30%
ATR (14)0.17
RSI (14)61.51
Beta4.44
Rel Volume0.62
Avg Volume144.22K
Volume89,007

Performance

Perf Week20.00%
Perf Month41.89%
Perf Quarter-30.00%
Perf Half Y-47.37%
Perf YTD-77.96%
Perf Year-73.97%
Perf 3Y-96.97%
Perf 5Y-99.95%
Perf 10Y-
Recom1.00
Target Price12.00
Prev Close2.25
Price2.10
Change %-6.67%

Peers

Mkt cap
TickerCompanyMkt cap
BMRABiomerica Inc6.95M
TRIBTrinity Biotech Plc ADR3.72M
CODXCo-Diagnostics Inc2.64M
QDELQuidelOrtho Corp817.18M
OSUROrasure Technologies Inc245.81M
PLSMPulsenmore Ltd12.43M
PRPOPrecipio Inc44.40M
IMDXInsight Molecular Diagnostics Inc78.21M
XGNExagen Inc121.98M
ISPCiSpecimen Inc1.79M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • Intelligent Bio Solutions Reports Record Fiscal First Quarter 2027 Revenue of $1.39 Million, Marking Sixth Consecutive Quarter of Year-Over-Year Growth (GlobeNewswire)
  • Intelligent Bio Solutions to Present at the Webull Biotech Webinar on November 12 (GlobeNewswire)
  • Intelligent Bio Solutions to Host Virtual Fireside Chat on September 24th at 4:30 p.m. ET (GlobeNewswire)
  • Intelligent Bio Solutions Submits FDA 510(k) Package for Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market Clearance (GlobeNewswire)
  • Intelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510(k) Submission (GlobeNewswire)
  • Intelligent Bio Solutions Announces Private Placement of up to $15 Million to a Single Existing Institutional Investor Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
  • Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth (GlobeNewswire) -17.08%
  • Intelligent Bio Solutions Strengthens Quality Management Credentials with ISO Recertification (GlobeNewswire) +21.66%
  • Intelligent Bio Solutions Announces Completion of Method Comparison Study for the Intelligent Fingerprinting Drug Screening System (GlobeNewswire)
  • Intelligent Bio Solutions Completes Usability Study Supporting FDA 510(k) Submission (GlobeNewswire)
  • Intelligent Bio Solutions Completes Interference Study Examining the Impact of Everyday Substances on Intelligent Fingerprinting System (GlobeNewswire)
  • Intelligent Bio Solutions Achieves Key Milestone Ahead of Planned FDA 510(k) Submission, Advancing Toward Planned U.S. Market Entry (GlobeNewswire)
  • Intelligent Bio Solutions Completes Precision Testing, Strengthening FDA 510(k) Submission Package Ahead of Planned Entry into Multi-Billion-Dollar U.S. Drug Screening Market (GlobeNewswire) -8.12%
  • Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2027Q12026-11-10-0.860-1.310-1.391.401
2026Q42026-08-19-1.580-1.580-1.3451.201.221
2026Q32026-05-13-1.800--1.7951.06--
2026Q22026-02-12-0.400-2.8160.905.501
2024Q42026-02-0596.000--8.0560.73--
2026Q12025-11-12--1.500-3.4901.114.801
2025Q42025-08-15-3.600--4.2200.84--
2025Q32025-05-13-4.400--4.4070.73--
2025Q22025-02-13-5.000--4.9590.61--
2025Q12024-11-07-7.000--7.0470.87--
2024Q32024-05-08-14.300-8.700-14.3170.821.201
2024Q22024-02-09-20.700-32.400-20.7410.761.001
2024Q12023-11-08-124.8-76.800-124.880.801.001
2023Q42023-08-24-518.4-178.8-136.920.130.602
2023Q32023-05-11-686.4-324-686.650.460.421
2023Q22023-02-14-55.200-13.200-55.5600.360.701

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2022FY-1,368-1,632-1,3590.441.98
2023FY-1,270-694.8-1,2701.261.75
2024FY-63.800--63.7693.11-
2025FY-20.000--20.0413.05-
2026FY-8.440-3.420-0.6804.224.29
2027FY--5.180--6.10
2028FY--4.060--8.80
2029FY--2.870--12.35

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2027Q2S2026-11-101101.401.401.40
2027Q2S2026-09-081101.401.401.40
2027Q2S2026-08-191001.381.381.38
2027Q2S2026-06-241001.381.381.38
2027Q2E2026-11-10100-1.36-1.36-1.36
2027Q2E2026-08-19100-1.36-1.36-1.36
2027Q2E2026-06-24100-1.36-1.36-1.36
2027Q1S2026-09-081011.401.401.40
2027Q1S2026-08-191001.421.421.42
2027Q1S2026-06-241001.421.421.42
2027Q1E2026-08-19100-1.31-1.31-1.31
2027Q1E2026-06-24100-1.31-1.31-1.31
2027FYS2026-09-081006.106.106.10
2027FYS2026-08-191006.136.136.13

Estimate history

EPS, annual-997.488-1457.712-628.608-1621.656-1359.312-1269.973-63.769-20.041-8.441-6.8151
Period201820192020202120222023202420252026TTM
EPS, quarterly-7.047-4.959-4.407-4.22-3.49-2.816-1.795-1.345-0.859
PeriodQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26Q1 '27
Sales, annual000001.2573.1123.0534.2154.5
Period201820192020202120222023202420252026TTM
Sales, quarterly0.8720.6070.7290.8441.1120.8971.0611.1461.392
PeriodQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26Q1 '27
Shares, annual0.0050.0050.0050.0060.0060.0190.3460.7322.9063.317
Period201820192020202120222023202420252026MRQ
Shares, quarterly0.4380.4810.6790.7320.911.2382.0012.9063.317
PeriodQ1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26Q1 '27

Income statement, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue4.504.223.053.111.260.000.000.000.00
Cost of Goods Sold Incl. D&A3.303.333.012.891.900.000.000.000.00
Gross Profit1.190.890.040.22-0.640.000.000.000.00
Selling, General and Administrative Excl. Other14.0813.8711.2810.938.538.777.192.795.83
Research and Development3.713.372.401.670.513.853.840.593.18
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-12.89-12.99-11.24-10.71-9.17-8.77-7.19-2.79-5.83
Interest Expense0.070.010.060.170.220.011.090.460.66
Unusual Expense0.040.300.22-0.182.000.000.360.250.90
Net Income Before Taxes-12.39-13.15-10.60-10.19-10.66-8.33-6.92-3.31-7.39
Income Taxes-0.25-0.680.000.000.000.000.000.000.00
Consolidated Net Income-12.14-12.47-10.60-10.19-10.66-8.33-7.06-3.19-7.39
Net Income From Continuing Operations-12.11-12.43-10.57-10.16-10.63-8.31-7.04-3.16-7.34
Net Income-12.11-12.43-10.57-10.16-10.63-8.31-7.04-3.16-7.34
EPS (Recurring)-3.90-8.30-19.75-64.54-1,102.38-1,359.30-1,563.73-593.22-1,333.07
EPS (Basic, Before Extraordinaries)-6.82-8.44-20.04-63.77-1,269.97-1,359.31-1,621.66-628.61-1,457.71
EPS (Diluted)-6.82-8.44-20.04-63.77-1,269.97-1,359.31-1,621.66-628.61-1,457.71
EBITDA-11.73-11.82-10.03-9.51-8.21-8.77-7.19-2.79-
Non-Operating Income (Expense)0.600.150.920.510.740.451.720.190.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-0.100.19------
Price To Sales Ratio1.150.802.970.982.22----
Gross Margin26.5221.021.287.21-50.93----
Operating Margin-286.70-308.11-368.27-344.11-729.92----
Net Margin-269.31-294.91-346.23-326.40-845.89----
Shares Outstanding3.322.910.730.350.020.010.010.010.01
Market Capitalization7.467.46118.8659.85777.4223,657.07117,085.14115,599.29-

Income statement, quarterly

Currency USD, millions
Metric2027Q12026Q42026Q32026Q22026Q12025Q42025Q32025Q2
Total Revenue1.391.151.060.901.110.840.730.61
Cost of Goods Sold Incl. D&A0.870.900.820.720.900.810.690.69
Gross Profit0.520.250.240.180.210.040.04-0.08
Selling, General and Administrative Excl. Other3.414.463.352.863.153.302.772.32
Research and Development0.831.470.890.520.490.580.360.51
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.89-4.21-3.11-2.68-2.93-3.27-2.73-2.40
Interest Expense0.000.000.000.060.000.010.020.01
Unusual Expense0.000.000.010.030.260.220.00-
Net Income Before Taxes-2.67-4.16-2.87-2.69-2.99-3.10-2.55-2.26
Income Taxes0.00-0.250.000.000.000.000.000.00
Consolidated Net Income-2.67-3.92-2.87-2.69-2.99-3.10-2.55-2.26
Net Income From Continuing Operations-2.66-3.91-2.86-2.68-2.98-3.09-2.54-2.25
Net Income-2.66-3.91-2.86-2.68-2.98-3.09-2.54-2.25
EPS (Recurring)-0.86-1.34-1.79-2.80-3.28-4.01-4.41-4.96
EPS (Basic, Before Extraordinaries)-0.86-1.34-1.80-2.82-3.49-4.22-4.41-4.96
EPS (Diluted)-0.86-1.34-1.80-2.82-3.49-4.22-4.41-4.96
EBITDA-2.59-3.92-2.82-2.40-2.63-2.97-2.42-2.09
Non-Operating Income (Expense)0.220.050.250.080.200.390.190.15
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.090.090.01-0.01---
Price To Sales Ratio1.151.581.362.532.654.132.832.09
Gross Margin37.4321.6823.0919.8319.334.185.40-13.51
Operating Margin-207.51-367.46-292.95-299.00-263.63-386.95-374.08-394.76
Net Margin-190.99-341.04-269.86-298.58-268.30-366.18-348.97-370.29
Shares Outstanding3.322.912.001.240.910.730.680.48
Market Capitalization7.465.496.699.1492.59118.8697.6861.42

Balance sheet, annual

Currency USD, millions
Metric2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments3.991.026.301.548.2412.570.430.200.42
Short Term Receivables1.671.600.980.832.473.210.020.090.04
Inventories0.420.640.780.980.000.000.000.000.00
Other Current Assets1.010.820.470.480.162.420.030.050.06
Total Current Assets7.104.078.533.8310.8718.210.480.350.51
Net Property, Plant & Equipment2.050.320.871.240.390.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.000.140.000.00
Long-Term Note Receivable---0.001.093.150.00--
Intangible Assets2.803.794.375.260.000.000.000.000.00
Deferred Tax Assets0.340.02-------
Other Assets0.000.070.000.030.000.501.861.981.98
Total Assets12.288.2713.7810.3512.3521.862.482.332.50
Short Term Debt Incl. Current Port. of LT Debt0.150.280.790.580.000.005.135.134.84
Accounts Payable0.710.900.601.200.721.360.480.900.17
Other Current Liabilities4.074.174.064.113.952.332.070.270.55
Total Current Liabilities4.935.355.455.884.663.687.696.315.56
Long Term Debt1.670.000.080.760.000.000.000.000.00
Provision for Risks Charges0.050.080.060.020.050.000.000.000.00
Deferred Tax Liabilities0.340.02-------
Other Liabilities0.000.000.000.000.000.020.000.000.00
Total Liabilities6.995.455.606.674.713.707.696.315.56
Non-Equity Reserves0.000.000.000.001.093.150.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.010.0215.038.72
Common Equity5.513.008.333.806.6215.04-5.21-19.65-13.09
Total Shareholders Equity5.513.008.333.806.6215.06-5.19-4.62-4.38
Accumulated Minority Interest-0.22-0.18-0.15-0.11-0.08-0.05-0.030.641.31
Total Equity5.292.818.183.696.5515.01-5.21-3.98-3.06
Total Liabilities & Stockholders Equity12.288.2713.7810.3512.3521.862.482.332.50
Book Value Per Share1.904.0924.10195.621,067.832,658.47-1,035.21-3,903.97-2,601.09
Tangible Book Value Per Share0.93-1.0811.45-75.001,067.832,658.47-1,035.21-3,903.97-2,601.09
Full-Time Employees5855505112995-
Price to Book Ratio0.9822.855.03204.64178.55426.83348.83--
Return on Assets-121.00-95.89-84.17-93.64-48.56-57.84-131.73-304.18-317.43
Return on Equity-292.25-186.64-167.49-203.99-76.61-142.58---
Return on Invested Capital-173.06-352.75-120.76-233.25-125.38-46.74---
Quick Ratio1.350.641.420.482.334.940.060.050.09
Current Ratio1.440.761.570.652.334.940.060.050.09

Cash flow, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-12.49-12.47-10.60-10.19-10.66-8.33-7.06-3.19-7.39
Depreciation1.191.161.211.210.97----
Other Funds (Non Cash)0.320.600.430.112.242.540.700.071.95
Funds from Operations-10.99-10.70-8.96-8.87-7.46-5.80-6.36-3.13-5.44
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.18-1.23-0.72-0.700.082.44-4.942.63-0.13
Cash from Operating Activities-12.17-11.93-9.68-9.57-7.38-3.36-11.30-0.50-5.58
Capital Expenditures-0.06-0.13-0.23-0.22-0.51-0.380.000.000.00
Net Assets From Acquisitions0.000.000.000.00-0.360.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.170.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.00-0.010.00
Purchase of Investments0.000.000.000.000.000.000.00-0.010.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.00-0.500.000.000.00
Other Sources0.040.040.000.000.000.000.000.000.00
Cash from Investing Activities-0.02-0.09-0.23-0.22-0.69-0.880.00-0.010.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock16.5314.984.6014.561.450.0023.400.885.32
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock16.5314.984.6014.561.450.0023.400.885.32
Proceedsfrom Stock Options11.0410.700.009.121.450.0022.890.885.32
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.00-0.150.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.00-0.010.000.000.000.00
Other Financing Activities Uses0.000.000.000.00-0.010.000.000.000.00
Cash from Financing Activities16.5314.984.6014.561.440.0023.400.735.32
Exchange Rate Effect0.010.000.03-0.00-0.06-0.100.040.010.04
Net Change in Cash4.352.97-5.284.77-6.70-4.3412.150.23-0.22
Free Cash Flow-12.22-12.05-9.91-9.79-7.88-3.74-11.30-0.50-5.58
Preferred Dividends (Cash Flow)-0.000.000.000.000.00---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2027Q12026Q42026Q32026Q22026Q12025Q4
Cash & Short Term Investments5.933.996.860.741.661.02
Short Term Receivables1.531.671.4510.361.641.60
Inventories0.480.420.600.590.630.64
Other Current Assets1.111.010.840.480.550.82
Total Current Assets9.057.109.7512.174.484.07
Net Property, Plant & Equipment1.982.052.112.212.080.32
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets2.602.803.003.273.473.79
Deferred Tax Assets-0.34---0.02
Other Assets0.000.000.000.000.000.07
Total Assets13.6212.2814.8617.6510.048.27
Short Term Debt Incl. Current Port. of LT Debt0.150.150.390.400.500.28
Accounts Payable3.674.133.644.263.994.53
Other Current Liabilities0.760.650.590.470.570.53
Total Current Liabilities4.584.934.615.135.065.35
Long Term Debt1.641.671.461.531.450.00
Provision for Risks Charges0.050.050.040.110.100.08
Deferred Tax Liabilities-0.34---0.02
Other Liabilities0.000.000.000.000.000.00
Total Liabilities6.276.996.116.766.615.45
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity7.585.518.9611.093.623.00
Total Shareholders Equity7.585.518.9611.093.623.00
Accumulated Minority Interest-0.23-0.22-0.21-0.20-0.19-0.18
Total Equity7.355.298.7510.893.432.81
Total Liabilities & Stockholders Equity13.6212.2814.8617.6510.048.27
Book Value Per Share2.291.904.488.963.984.09
Tangible Book Value Per Share1.500.932.986.320.16-1.08
Full-Time Employees-58---55
Price to Book Ratio0.980.510.3723.9424.9322.85
Return on Assets-102.34-121.00-95.01-85.77-99.85-95.89
Return on Equity-216.11-292.25-165.02-146.12-223.45-186.64
Return on Invested Capital-28.84-54.40-27.47-21.21-58.83-103.14
Quick Ratio1.871.351.982.260.760.64
Current Ratio1.981.442.112.370.890.76

Cash flow, quarterly

Currency USD, millions
Metric2027Q12026Q42026Q32026Q22026Q12025Q4
Net Income-2.67-4.10-3.01-2.71-2.99-3.15
Depreciation0.290.300.300.280.300.31
Other Funds (Non Cash)0.120.13-0.040.100.420.28
Funds from Operations-2.26-3.66-2.74-2.33-2.27-2.55
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.500.32-1.740.74-0.580.30
Cash from Operating Activities-2.75-3.34-4.48-1.59-2.85-2.25
Capital Expenditures0.00-0.000.01-0.07-0.07-0.21
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.00-0.040.000.040.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.040.000.000.000.00
Cash from Investing Activities0.00-0.000.01-0.03-0.07-0.21
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock4.680.4410.700.693.560.63
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock4.680.4410.700.693.560.63
Proceedsfrom Stock Options0.279.580.510.680.22-3.95
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities4.680.4410.700.693.560.63
Exchange Rate Effect0.010.000.000.00-0.000.03
Net Change in Cash1.94-2.906.24-0.920.64-1.81
Free Cash Flow-2.75-3.34-4.47-1.66-2.92-2.46

Revenue breakdown

Other sales - accessories2025: 578.64K 2026: 827.35K
Sales of Goods - Cartidges2025: 1.76M 2026: 2.49M
Sales of Goods - Readers2025: 711.74K 2026: 902.26K
Americas2025: 22.64K 2026: 8.75K
Asia Pacific2025: 29.17K 2026: 12.47K
Other Country2025: 132.70K 2026: 40.20K
United Kingdom2025: 2.87M 2026: 4.15M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.97%0.1M3.2M144.50K
2026-10-152.83%0.1M3.2M157.45K
2026-09-301.81%0.1M3.2M158.80K
2026-09-153.71%0.1M3.2M159.98K
2026-08-311.15%0.0M2.9M80.19K
2026-08-143.61%0.1M2.9M84.65K
2026-07-312.15%0.0M2.3M107.68K
2026-07-154.49%0.1M2.3M109.53K
2026-06-303.70%0.1M2.3M121.10K
2026-06-154.63%0.1M2.3M121.04K
2026-05-294.00%0.1M2.3M119.20K
2026-05-156.54%0.1M2.3M132.78K
2026-04-302.86%0.1M1.9M105.46K
2026-04-151.41%0.0M1.9M115.40K
2026-03-312.24%0.0M2.0M657.20K
2026-03-132.79%0.0M1.6M2.44M
2026-02-275.94%0.1M1.6M2.39M
2026-02-132.11%0.0M1.6M2.37M
2026-01-3010.99%0.1M1.2M2.36M
2026-01-1530.79%0.4M1.2M2.30M

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-108-KCurrent report2026-11-10SEC
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-02ARSAnnual report to security holders. 2026-06-30SEC
2026-11-02DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-02SEC
2026-10-23PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-23SEC
2026-10-2110-K/A2026-06-30SEC
2026-10-138-KCurrent report2026-10-12SEC
2026-09-23EFFECTEffectiveness filing by commission orderSEC
2026-09-23424B3SEC
2026-09-15S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-09-14DNotice of sales of securities on Form D (Regulation D)SEC
2026-09-118-KCurrent report2026-09-10SEC
2026-09-098-KCurrent report2026-09-09SEC
2026-09-028-KCurrent report2026-08-31SEC
2026-09-018-KCurrent report2026-09-01SEC
2026-08-288-KCurrent report2026-08-28SEC
2026-08-198-KCurrent report2026-08-19SEC
2026-08-1910-KAnnual report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-118-KCurrent report2026-08-11SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-08-038-KCurrent report2026-08-03SEC
2026-08-038-KCurrent report2026-07-31SEC
2026-07-238-KCurrent report2026-07-23SEC
2026-07-218-KCurrent report2026-07-21SEC
2026-06-168-KCurrent report2026-06-16SEC
2026-06-028-KCurrent report2026-06-02SEC
2026-05-15SCHEDULE 13GSEC
2026-05-148-KCurrent report2026-05-13SEC
2026-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
ARMISTICE CAPITAL, LLC5.91%
GEODE CAPITAL MANAGEMENT, LLC0.54%
StoneX Group Inc.0.34%
VANGUARD CAPITAL MANAGEMENT LLC0.24%
VANGUARD FIDUCIARY TRUST CO0.17%
Tower Research Capital LLC0.14%
UBS Group AG0.04%
OSAIC HOLDINGS, INC.0.01%
BARCLAYS PLC0.01%

Funds

Fund% owned
Fidelity Extended Market Index Fund0.41%
VANGUARD EXTENDED MARKET INDEX FUND0.24%
Fidelity Nasdaq Composite Index Fund0.08%
Fidelity Series Total Market Index Fund0.06%
Fidelity Total Market Index Fund0.01%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. INBS. Cached 15 minutes.

Some panels did not load: ratings, insider.